CAZZANIGA, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 21.565
EU - Europa 10.053
AS - Asia 5.270
SA - Sud America 321
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 16
Totale 37.305
Nazione #
US - Stati Uniti d'America 21.294
SG - Singapore 2.128
RU - Federazione Russa 1.984
IT - Italia 1.967
CN - Cina 1.490
IE - Irlanda 1.379
SE - Svezia 1.299
DE - Germania 1.182
HK - Hong Kong 983
UA - Ucraina 725
GB - Regno Unito 402
BR - Brasile 266
CA - Canada 258
FI - Finlandia 253
FR - Francia 221
AT - Austria 212
VN - Vietnam 166
ID - Indonesia 158
NL - Olanda 108
TR - Turchia 104
IN - India 92
DK - Danimarca 72
BE - Belgio 63
JP - Giappone 40
ES - Italia 37
ZA - Sudafrica 24
AR - Argentina 20
CH - Svizzera 19
PL - Polonia 18
BG - Bulgaria 17
CZ - Repubblica Ceca 17
EU - Europa 16
GR - Grecia 15
IR - Iran 15
AU - Australia 14
PT - Portogallo 12
NO - Norvegia 11
RO - Romania 11
KR - Corea 10
EG - Egitto 9
IQ - Iraq 9
PK - Pakistan 9
EC - Ecuador 8
MX - Messico 7
BD - Bangladesh 6
CL - Cile 6
MU - Mauritius 6
PE - Perù 6
TH - Thailandia 6
UZ - Uzbekistan 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
HU - Ungheria 5
MA - Marocco 5
PH - Filippine 5
TW - Taiwan 5
AZ - Azerbaigian 4
BO - Bolivia 4
EE - Estonia 4
IL - Israele 4
KZ - Kazakistan 4
RE - Reunion 4
SA - Arabia Saudita 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
KG - Kirghizistan 3
PA - Panama 3
PY - Paraguay 3
BY - Bielorussia 2
CO - Colombia 2
DZ - Algeria 2
LK - Sri Lanka 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MY - Malesia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
A1 - Anonimo 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CI - Costa d'Avorio 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GL - Groenlandia 1
IM - Isola di Man 1
KE - Kenya 1
LB - Libano 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
OM - Oman 1
Totale 37.301
Città #
Ann Arbor 3.634
Fairfield 2.292
Woodbridge 2.114
Houston 1.639
Singapore 1.405
Dublin 1.347
Chandler 1.252
Ashburn 1.158
Wilmington 1.061
Hong Kong 976
Seattle 874
Cambridge 798
Frankfurt am Main 775
Jacksonville 755
Dearborn 605
Milan 578
New York 542
Santa Clara 506
Princeton 492
Lawrence 239
Nanjing 227
Altamura 224
Moscow 206
Shanghai 195
Vienna 166
Beijing 164
Jakarta 147
San Diego 147
Lachine 124
Los Angeles 91
Helsinki 83
Dong Ket 80
Andover 79
Nanchang 77
Lissone 76
Council Bluffs 75
Toronto 72
Guangzhou 69
Hefei 68
Nuremberg 65
Rome 64
Shenyang 63
Fuzhou 59
Brussels 57
Hebei 55
Boardman 54
London 54
Tianjin 51
Changsha 48
Jinan 48
Chicago 44
Norwalk 41
Falls Church 34
Jiaxing 32
Munich 30
Ningbo 29
Ottawa 29
Paris 29
Zhengzhou 29
Hangzhou 27
Monza 27
Kunming 26
Besana In Brianza 25
Fremont 25
Pune 25
Turin 25
Redmond 24
São Paulo 24
Turku 24
Kocaeli 23
Mountain View 23
Como 22
Dallas 22
Bologna 21
Huizen 20
Padova 20
The Dalles 18
Cinisello Balsamo 17
Göttingen 17
San Mateo 17
Florence 16
Lappeenranta 15
Sesto San Giovanni 15
Edmonton 13
Grafing 13
San Francisco 13
Seregno 13
Taizhou 13
Carate Brianza 12
Düsseldorf 12
Naples 12
Athens 11
Bergamo 11
Brugherio 11
Desio 11
Nürnberg 11
Phoenix 11
Tokyo 11
Washington 11
Zurich 11
Totale 27.045
Nome #
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 371
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 338
NIPBL: a new player in myeloid cells differentiation 326
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 320
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 308
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 296
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 292
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 289
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 285
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 282
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 278
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 269
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 266
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 265
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 252
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 251
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 237
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 234
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 231
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 226
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 222
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 219
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 217
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 215
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 214
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 214
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 213
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 208
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 205
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 204
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 204
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 203
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 201
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 200
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 199
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation 198
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 198
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 198
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 198
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 197
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 197
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 196
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 193
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 193
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 193
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 192
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 192
CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies 191
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions 191
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 189
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 188
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 187
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 186
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 185
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 184
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 184
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 183
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 183
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 180
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 180
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 179
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol 176
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 175
Rings and bricks: Expression of cohesin components is dynamic during development and adult life 175
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 174
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 174
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 173
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 173
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis 172
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 172
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 172
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 171
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 170
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 170
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 170
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 170
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 170
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia 169
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 168
Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia 167
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 167
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 167
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 167
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 167
TEL/ARG induces cytoskeletal abnormalities in 293T cells 166
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 166
In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice 165
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 165
Metabolic gatekeeper function of B-lymphoid transcription factors 164
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia 163
γ-Catenin-Dependent Signals Maintain BCR-ABL1 + B Cell Acute Lymphoblastic Leukemia 163
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 161
Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients 160
T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses 160
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 159
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 159
Novel activating mutations lacking cysteine in type i cytokine receptors in acute lymphoblastic leukemia 158
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 158
The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia 156
Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Ph– B-Cell Precursor Acute Lymphoblastic Leukemia 156
Totale 20.197
Categoria #
all - tutte 146.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.949


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020474 0 0 0 0 0 0 0 0 0 0 317 157
2020/20215.491 222 341 432 474 446 436 816 678 399 494 350 403
2021/20223.278 232 342 419 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20244.081 119 130 173 185 528 1.087 816 152 357 85 81 368
2024/20258.002 466 1.067 552 447 866 311 662 292 1.069 1.516 754 0
Totale 38.504